The study conducted by Birgitte et al. revealed that prothrombin G20210A mutations and factor V Leiden R506Q accounted for 10% and 1%, respectively, of the population-attributable risk for venous thromboembolism and non-O blood type, respectively, for 20% of the population. This evidence concerns the gene F2 and venous thromboembolism.